Oral Sucralfate in Acute Radiation Oesophagitis

Sur, Ranjan; Kochhar, Rakesh; Singh, Deepinder

doi:10.3109/02841869409098377

Cited by 42 publications

(26 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given the wide use of a four-point categorical severity scale, this is inevitably defined as an improvement in symptom rating by one or more categories (Sur et al, 1994;MRC LCWP, 1991, 1992. Inevitably, patients without the symptom at presentation are excluded.…”

Section: Improvementmentioning

confidence: 99%

See 1 more Smart Citation

Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise

Stephens¹,

Hopwood

Girling³

1999

Br J Cancer

View full text Add to dashboard Cite

The assessment of symptom palliation is an essential component of many treatment comparisons in clinical trials, yet an extensive literature search revealed no consensus as to its precise definition, which could embrace relief of symptoms, time to their onset, duration, degree, as well as symptom control and prevention. In an attempt to assess the importance of these aspects and to compare different methods of analysis, we used one symptom (cough) from a patient self-assessment questionnaire (the Rotterdam Symptom Checklist) in a large (>300 patient) multicentre randomized clinical trial (conducted by the Medical Research Council Lung Cancer Working Party) of palliative chemotherapy in small-cell lung cancer. The regimens compared were a two-drug regimen (2D) and a four-drug regimen (4D). No differences were seen between the regimens in time of onset of palliation or its duration. The degree of palliation was strongly related to the initial severity: 90% of the patients with moderate or severe cough at baseline reported improvement, compared with only 53% of those with mild cough. Analyses using different landmark time points gave conflicting results: the 4D regimen was superior at 1 month and at 3 months, whereas at 2 months the 2D regimen appeared superior. When improvement at any time up to 3 months was considered, the 4D regimen showed a significant benefit (4D 79%, 2D 60%, P = 0.02). These findings emphasize the need for caution in interpreting results, and the importance of working towards a standard definition of symptom palliation. The current lack of specified criteria makes analysis and interpretation of trial results difficult, and comparison across trials impossible. A standard definition of palliation for use in the analysis of clinical trials data is proposed, which takes into account aspects of onset, duration and degree of palliation, and symptom improvement, control and prevention. © 1999 Cancer Research Campaign

show abstract

Section: Improvementmentioning

confidence: 99%

“…sucralfate to palliate acute radiation oesophagitis (Sur et al, 1994) or granisetron as an antiemetic in cytostatic-induced emesis (Marty et al, 1992)]. Occasionally, when treatment affects a number of symptoms, the individual symptoms are listed and their palliation reported [e.g.…”

mentioning

confidence: 99%

Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise

Stephens¹,

Hopwood

Girling³

1999

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…[7][8][9][10][11][12][13] Small studies have suggested a modest reduction in radiation-induced enteritis in the pelvis. [14][15][16][17][18] However, studies investigating the use of sucralfate in radiotherapy to the esophagus, 19,20,21 skin, 22 and head and neck 12,21,[23][24][25][26] have been mixed.…”

mentioning

confidence: 99%

Double blind randomized trial of sucralfate vs placebo during radical radiotherapy for head and neck cancers

et al. 1999

View full text Add to dashboard Cite

“…Although research has been performed regarding pharmaceutical management of AET, there are no guidelines to address this problem. Demonstration has been made of the difference in pain in esophageal cancer patients receiving sucralfate or sodium alginate for AET following external beam and intracavitary RT (17). In the sucralfate group, patients had a significant relief of symptoms within 7 days of treatment and it was detected endoscopically that most ulcers had healed by 12 days of treatment.…”

Section: Discussionmentioning

confidence: 99%

Overcoming toxicity-challenges in chemoradiation for non-small cell lung cancer

Uyterlinde

2016

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Concurrent chemoradiation (CCRT) is the treatment of choice for locally advanced non-small cell lung cancer (NSCLC) with a modest survival benefit over sequential chemoradiation or radiotherapy (SCRT) alone. However, this benefit is at the cost of increasing acute toxicity such as esophagitis. Previous analysis revealed several predictive parameters in dose-volume and patient characteristics which helped us to identify those patients at risk for severe esophagus toxicity. As a result, supportive care interventions including individualized patient information, dietary guidance, adequate medication, hydration and tubefeeding could be initiated. This paper discusses the challenges in overcoming chemoradiation induced acute esophageal toxicity (AET).

show abstract

Oral Sucralfate in Acute Radiation Oesophagitis

Cited by 42 publications

References 12 publications

Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise

Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise

Double blind randomized trial of sucralfate vs placebo during radical radiotherapy for head and neck cancers

Overcoming toxicity-challenges in chemoradiation for non-small cell lung cancer

Contact Info

Product

Resources

About